Bptetra250 mg

Bptetra is a broad-spectrum tetracycline-class antibiotic used to treat a range of bacterial and certain non-bacterial infections. Because bacterial resistance to tetracyclines is common, it should be used only when the infecting organism is proven or strongly suspected to be susceptible.

Established / FDA-labeled uses

• Infections caused by susceptible strains of Gram-positive and Gram-negative organisms, including respiratory tract infections, skin and soft tissue infections, and urinary tract infections.
• Rocky Mountain spotted fever, typhus fever and other rickettsioses.
• Chlamydial infections, including psittacosis, lymphogranuloma venereum, and uncomplicated urethral, endocervical, or rectal infections.
• Relapsing fever (Borrelia), brucellosis (usually combined with an aminoglycoside), tularemia, cholera, and granuloma inguinale.
• Syphilis and gonorrhea in patients who are allergic to penicillin.

Guideline-supported / adjunct uses

• Moderate to severe inflammatory acne vulgaris, as an adjunct to topical therapy.
• As part of multidrug combination regimens for Helicobacter pylori eradication in peptic ulcer disease.
• Adjunctive therapy in intestinal amoebiasis (used together with an amoebicide).

Bptetra is not effective against viral infections and inappropriate use increases the risk of drug-resistant bacteria.

Each capsule/tablet contains Tetracycline Hydrochloride as the active pharmaceutical ingredient, formulated as an oral solid dosage form (capsule or film-coated tablet) in commonly available strengths of 250 mg and 500 mg. Inactive ingredients vary by manufacturer and formulation.

Bptetra is the hydrochloride salt of tetracycline, a naturally derived and semi-synthetic broad-spectrum antibiotic belonging to the tetracycline class. It is active against a wide range of Gram-positive and Gram-negative bacteria as well as atypical organisms such as chlamydiae, mycoplasmas, and rickettsiae.

It is supplied as oral capsules/tablets for systemic use and is one of the older, well-characterized members of the tetracycline family, distinguished from newer agents (e.g., doxycycline, minocycline) mainly by its shorter half-life and requirement for more frequent dosing.

Tetracycline-class antibiotic (broad-spectrum bacteriostatic antimicrobial)

Mechanism of Action

Tetracycline Hydrochloride is a bacteriostatic antibiotic that inhibits bacterial protein synthesis. It binds reversibly to the 30S ribosomal subunit of susceptible bacteria, blocking the attachment of aminoacyl-tRNA to the mRNA-ribosome complex, thereby preventing addition of new amino acids to the growing peptide chain.

Pharmacokinetics

• Absorption: Incompletely absorbed after oral administration (roughly 60-80%); absorption is significantly reduced by food, dairy products, and polyvalent cations.
• Peak plasma concentration: Reached approximately 2-4 hours after an oral dose.
• Distribution: Widely distributed into most body tissues and fluids; concentrates in bone and developing teeth; crosses the placenta and is excreted into breast milk.
• Elimination half-life: Approximately 6-12 hours.
• Excretion: Primarily via the kidneys (glomerular filtration) with additional excretion in bile and feces; undergoes enterohepatic recirculation.

Bptetra should be taken orally with a full glass of water, on an empty stomach (1 hour before or 2 hours after food), while remaining upright for at least 30 minutes afterward. Avoid concurrent intake of dairy products, antacids, or mineral supplements (calcium, iron, zinc, magnesium) — space these at least 2 hours apart from the dose. Complete the entire prescribed course exactly as directed.

Clinically Significant Drug Interactions

• Antacids and mineral supplements (calcium, magnesium, aluminum, iron, zinc, bismuth subsalicylate): Form insoluble chelate complexes with Bptetra, substantially reducing its absorption and clinical efficacy. Separate administration by at least 2 hours.
• Dairy products and calcium-fortified foods/beverages: Similarly chelate the drug and reduce absorption; avoid taking together.
• Oral anticoagulants (e.g., warfarin): Bptetra may depress plasma prothrombin activity and potentiate anticoagulant effect; anticoagulant dose may need adjustment and INR should be monitored.
• Oral contraceptives: May reduce contraceptive efficacy and increase breakthrough bleeding; an additional non-hormonal method of contraception is advised during treatment.
• Penicillin-class antibiotics: Bacteriostatic tetracyclines may interfere with the bactericidal action of penicillins; concurrent use is generally avoided.
• Methoxyflurane and other potentially nephrotoxic drugs: Concurrent use has been associated with fatal nephrotoxicity; avoid combination.
• Retinoids (e.g., isotretinoin, acitretin): Increased risk of intracranial hypertension (pseudotumor cerebri) when combined with tetracyclines; avoid concurrent use.

Common Side Effects

• Nausea, vomiting, diarrhea, abdominal discomfort, and loss of appetite
• Photosensitivity (exaggerated sunburn reaction) with sun or UV light exposure
• Glossitis, stomatitis, and dysphagia

Less Common but Serious Effects

• Esophageal irritation or ulceration (see Precautions and Warnings for prevention)
• Clostridioides difficile-associated diarrhea/colitis, ranging from mild to severe
• Intracranial hypertension (pseudotumor cerebri) presenting as headache and visual disturbance
• Hypersensitivity reactions: rash, urticaria, angioedema, and rarely anaphylaxis or serum sickness-like reactions
• Hematologic effects: hemolytic anemia, thrombocytopenia, neutropenia, eosinophilia
• Hepatotoxicity (rare, more often with high intravenous doses)
• Permanent tooth discoloration and enamel hypoplasia when used in young children or during pregnancy (see Contraindications)

Pregnancy: Bptetra is contraindicated during pregnancy. It crosses the placenta and can cause permanent discoloration of the fetus's teeth, enamel hypoplasia, and inhibition of bone growth, particularly with exposure during the second and third trimesters. It should not be used during pregnancy unless the treating physician determines it is absolutely necessary and no safer alternative exists.

Lactation: Bptetra is excreted into breast milk. Although calcium in milk may partially limit infant absorption, use during breastfeeding is generally not recommended due to the potential for tooth discoloration and effects on bone growth in the infant. Use only if clearly needed and the potential benefit justifies the potential risk to the infant; consult a physician before use while breastfeeding.

• Antibiotic stewardship: Take Bptetra exactly as prescribed by your physician; do not stop, extend, skip doses, or share this medicine with others without medical advice, and complete the full prescribed course.
• Photosensitivity: Avoid prolonged sun/UV exposure and use sun protection (protective clothing, sunscreen); discontinue at the first sign of skin erythema.
• Esophageal irritation: Take with a full glass of water and remain upright for at least 30 minutes after each dose to minimize risk of esophageal irritation or ulceration.
• Reduced absorption: Do not take together with dairy products, antacids, or calcium/iron/zinc/magnesium-containing supplements; separate dosing by at least 2 hours (see Interactions).
• Tooth/bone effects and pregnancy/pediatric contraindication: See Contraindications and Pregnancy and Lactation.
• C. difficile-associated diarrhea: May occur during or up to several weeks after treatment; seek medical attention for persistent or severe diarrhea.
• Intracranial hypertension: Discontinue promptly and seek medical care if headache, blurred vision, or visual disturbance occurs.
• Superinfection: Prolonged use may result in overgrowth of non-susceptible organisms, including fungi (e.g., oral or vaginal candidiasis).
• Renal/hepatic disease: Use with caution; may worsen azotemia in patients with renal impairment (see Use in Special Populations).

There is no specific antidote for Bptetra overdose, and the drug is not effectively removed by dialysis. In case of a suspected overdose, discontinue the medication immediately and seek immediate medical attention or contact a poison control center/emergency services. Treatment is supportive and symptomatic, guided by a physician; do not attempt specific home treatment.

Store at room temperature (below 30°C), away from light and moisture, in a tightly closed, light-resistant container. Keep out of reach of children.

Renal Impairment

Bptetra can further impair renal function and cause accumulation with resultant azotemia in patients with significant renal impairment; use with caution and under close medical supervision, with dose adjustment as directed by the physician if used at all.

Hepatic Impairment

Use with caution in patients with hepatic impairment; high-dose therapy has been associated with hepatotoxicity, particularly in pregnant women and those with pre-existing liver disease.

Elderly

No specific dose adjustment is established for elderly patients with normal renal function, but age-related decline in renal function should be considered; monitor closely.

Pediatric Patients

Contraindicated in children under 8 years except in special circumstances directed by a physician (see Contraindications and Pediatric Uses).

Duration varies by indication and is determined by the treating physician, typically ranging from 7 to 14 days for most bacterial infections, up to 3 weeks for conditions such as brucellosis, and longer, tapering courses for acne. Regardless of indication, the full prescribed course of Bptetra should be completed even if symptoms improve before completion, to reduce the risk of relapse and antibiotic resistance.

Tetracyclines

Tetracycline Hydrochloride exerts a bacteriostatic effect by reversibly binding to the 30S ribosomal subunit of susceptible bacteria, thereby blocking binding of aminoacyl-tRNA to the mRNA-ribosome complex and inhibiting bacterial protein synthesis. This halts bacterial growth and replication, allowing host immune defenses to clear the infection.

D

Bptetra is contraindicated in children under 8 years of age because it can cause permanent tooth discoloration, enamel hypoplasia, and inhibition of bone growth during the period of tooth and bone development. It may be used in this age group only in specific special circumstances (e.g., anthrax post-exposure prophylaxis when no alternative is suitable) strictly under a physician's direction after weighing risks and benefits.

In children over 8 years of age, safety and efficacy are established; the usual dose is 25-50 mg/kg/day in 4 divided doses, not to exceed the adult dose, with the same administration precautions (empty stomach, avoid dairy/mineral supplements, full glass of water) as in adults.